The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

Inclusion Criteria Concurrent Medication: Allowed: * Treatment or suppression of opportunistic infections with standard drugs. * Pneumovax, HIB, tetanus, influenza, and hepatitis B vaccines. * Clinically indicated antibiotics. * Short courses of steroids (\< 21 days) for acute problems not related to hepatitis C. * Other regularly prescribed medications such as analgesics, nonsteroidal anti-inflammatory agents, antipyretics, allergy medications, and oral contraceptives. Patients must have: * HIV positivity. * Documented hepatitis C virus. * CD4 count \<= 200 cells/mm3. * No severe liver disease (Grade C Childs-Pugh classification) or chronic liver disease not caused by hepatitis C. * Willingness to be followed for the duration of treatment and follow-up period. Prior Medication: Allowed: * Prior AZT, ddI, and ddC. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Hepatitis B (HBsAg positive). * Autoimmune hepatitis (FANA titer \>= 1:160 and anti-smooth muscle antibody titer \>= 1:160). * Wilson's disease. * alpha-1 antitrypsin deficiency. * Hemochromatosis. * Malignancy requiring systemic chemotherapy. Concurrent Medication: Excluded: * Nonnucleoside analog therapy for HIV. * Biologic response modifiers. * Systemic cytotoxic chemotherapy. * Chronic systemic steroid use. Concurrent Treatment: Excluded: * Radiation therapy other than local irradiation to the skin. Prior Medication: Excluded: * Prednisone within 12 weeks prior to study entry (if patient has received prior daily doses for 1 month or longer duration). * Acute therapy for an infection within 2 weeks prior to study entry.